Evaluation of the combination treatment docetaxel and JQ1 in 2D and 3D preclinical models of prostate cancer
- Alternative title
-
Bewertung der Kombinationsbehandlung Docetaxel und JQ1 in präklinischen 2D- und 3D-Modellen von Prostatakrebs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Berlin, Medizinische Fakultät Charité - Universitätsmedizin Berlin, Dissertation, 2023
- Keyword
-
Therapie
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Medizinische Fakultät Charité - Universitätsmedizin Berlin
- (when)
-
2023
- Creator
- DOI
-
10.17169/refubium-40797
- URN
-
urn:nbn:de:kobv:188-refubium-41076-1
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:47 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Xu, Yipeng
- Medizinische Fakultät Charité - Universitätsmedizin Berlin
Time of origin
- 2023
Other Objects (12)
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Mechanistic analysis and preclinical validation of novel combination therapies targeting metastatic progression
Radiochemistry and preclinical PET imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane antigen
Acquired resistance to irradiation or docetaxel is not associated with cross‑resistance to cisplatin in prostate cancer cell lines
Evaluation of 2D combination of eye-tracking metrics for task distinction
Preclinical hyperthermia
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Mechanistic analysis and preclinical validation of novel combination therapies targeting metastatic progression
Radiochemistry and preclinical PET imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane antigen
Acquired resistance to irradiation or docetaxel is not associated with cross‑resistance to cisplatin in prostate cancer cell lines
Evaluation of 2D combination of eye-tracking metrics for task distinction
Preclinical hyperthermia
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Shikonin reduces growth of docetaxel-resistant prostate cancer cells mainly through necroptosis
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
Docetaxel in the management of PSA progression following primary androgen deprivation for prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Mechanistic analysis and preclinical validation of novel combination therapies targeting metastatic progression
Radiochemistry and preclinical PET imaging of 68Ga-desferrioxamine radiotracers targeting prostate-specific membrane antigen
Acquired resistance to irradiation or docetaxel is not associated with cross‑resistance to cisplatin in prostate cancer cell lines
Evaluation of 2D combination of eye-tracking metrics for task distinction